Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,631 | Dovepress* | 7,510+ | 1,181 | 8,691 | |
PubMed Central* | 1,121 | 422 | 1,543 | ||
Totals | 8,631 | 1,603 | 10,234 | ||
*Since 4 August 2016 |
View citations on PubMed Central and Google Scholar